Skip to main content
Clinical Trials/EUCTR2017-001296-23-NL
EUCTR2017-001296-23-NL
Active, Not Recruiting
Phase 1

The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial

Radboudumc0 sites92 target enrollmentJuly 7, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with >6 months or recurrent episodes of abdomino-perineo-pelvic pain, hypersensitivity or discomfort often associated with elimination changes, and sexual dysfunction in the absence of organic etiology (definition of the International Continence Society (ICS)) with (primary of secondary) pelvic floor muscle hypertonicity refractory to first line pelvic floor physiotherapy, willing to participate in this trial.
Sponsor
Radboudumc
Enrollment
92
Status
Active, Not Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 7, 2017
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Radboudumc

Eligibility Criteria

Inclusion Criteria

  • \-Female, \>18 years
  • \-Chronic pelvic pain according to the ICS with or without dyspareunia
  • \-Vaginal examination with one finger possible
  • \-Pelvic floor hypertonicity measured by physical examination by registered pelvic floor physiotherapist
  • \-Previous physical therapy with registered physical therapist was unsuccessful
  • \-Good understanding of Dutch language
  • \-Willing to provide informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • \-(wish for) Pregnancy/lactation
  • \-Previous pelvic floor BTA treatment
  • \-Known hypersensitivity to BTA
  • \-History of neuromuscular or bleeding disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials